The latest figures for the amount of money spent by the pharmaceutical industry on the medical profession for the U.K. has been revealed — £41 million ($60 million). This is dwarfed by the amount spent in the U.S.
It has been a mixed week for the pharmaceutical sector in terms of drug development, with success for Novartis and disappointing news for Boehringer and Vitae Pharma. Digital Journal reports on the latest news.
The Federal Court of Australia has rejected an appeal of a ruling that allows companies to patent isolated human genes. This reignites the debate: who owns your genes - you or the company that extracts them?
Japan's biggest pharmaceutical company has been hit with a $6 billion penalty for concealing cancer risks associated with its Actos diabetes drug while Eli Lilly and Co, Takeda's co-defendant in the case, was ordered to pay $3 billion in punitive damages.
The pharmaceutical company Mylan has voluntarily recalled three types of painkiller tablets due to the risk that the tablets are more potent than the label indicates. The risk is that consumers could overdose.
Following the reports about the contaminated sterile medicines produced by the NEEC pharmacy, the State of Massachusetts has closed three more compounding pharmacies due to concerns over risks to patients.
A Frenchman suffering from Parkinson's disease who claimed he developed addictions to gambling and sex following treatment with a drug made by pharmaceutical giant GlaxoSmithKline (GSK), has been awarded substantial damages.
One of the most tragic cases associated with medicines was the thalidomide scandal of the 1950s and 1960s, where improperly tested medicines were given to pregnant women. Some fifty years on, the company responsible have issued a public apology.
A vast stock of a typhoid vaccine, intended to immunize travelers against typhoid fever, has been recalled by the pharmaceutical company who manufactured it. The reason for the recall was that the vaccine simply did not work.